MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
An Introduction to Exosome Therapy And Its Costs
Are you curious about how exosomes relate to conversations about stem cells? Maybe you’ve heard of exosome therapy and its regenerative capabilities.
But what exactly is exosome therapy and what are its benefits? Keep reading for an introduction to exosomes so you can better understand how this therapy is advancing the field of modern medicine as we know it. [Read more…]
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis
U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects
CAMBRIDGE, Mass.–MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the United States. This procedure was performed by Dr. Justin Newman at Orthopedic Centers of Colorado. [Read more…]
Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs
Japanese government-certified clinic applies ISCT-compliant flow-cytometry release criteria to patient-specific adipose-derived stem cell cultures, serving patients from approximately 20 countries [Read more…]
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy
SHANGHAI, June 23, 2026 — UniXell Biotechnology Co., Ltd. (“UniXell”) has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson’s disease. Paired with the prior IND approval from China’s National Medical Products Administration (NMPA) on June 3, 2026, the candidate will undergo clinical development in both China and the United States concurrently, marking a landmark dual-country breakthrough for the company’s neurodegenerative disease pipeline. This milestone solidifies UniXell’s unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics.
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 339
- Next Page »